The Glo-BNHL trial, sponsored by the University of Birmingham, aims to address a significant unmet medical need in the treatment of relapsed and refractory B-cell non-Hodgkin lymphoma (B-NHL) in pediatric and adolescent populations. Current treatment regimens yield a low cure rate of approximately 30%, highlighting the necessity for novel therapeutic options. The trial's adaptive design allows for the continuous evaluation of multiple investigational agents, including bispecific antibodies, antibody-drug conjugates, and CAR T-cell therapies. This flexibility may enhance the likelihood of identifying effective treatments, potentially positioning the trial as a pivotal study in this niche market. Collaborations with industry partners such as Regeneron Pharmaceuticals and ADC Therapeutics S.A. may also facilitate access to advanced therapeutic modalities and bolster competitive positioning in the pediatric oncology landscape.